1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Body Weight in 22 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Currently, obesity is considered a systemic inflammation; however, the effects of obesity on the vulnerability of dopaminergic neurons to oxidative stress are not fully defined." | 5.33 | Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. ( Choi, JY; Jang, EH; Kang, JH; Park, CS, 2005) |
| "Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice." | 1.62 | Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier. ( Cui, C; Hong, H; Huang, SB; Jia, XB; Qiao, CM; Shen, YQ; Shi, Y; Wu, J; Yao, L; Zhao, WJ; Zhou, Y, 2021) |
| "SUN N8075 is a novel antioxidant with neuroprotective properties." | 1.35 | Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease. ( Adachi, T; Hara, H; Izuta, H; Matsunaga, N; Oida, Y; Oyagi, A; Shimazawa, M, 2008) |
| "Currently, obesity is considered a systemic inflammation; however, the effects of obesity on the vulnerability of dopaminergic neurons to oxidative stress are not fully defined." | 1.33 | Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. ( Choi, JY; Jang, EH; Kang, JH; Park, CS, 2005) |
| " In study 1, the authors examined the effect of V-10,367 (50 mg/kg x 2 per day, by mouth) on neurofilament M (NFM) protein levels and on alpha-spectrin breakdown products (SBDPs) when dosed for 2 days, starting 24 hours after TBI and killed on day 3." | 1.31 | Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury. ( Detloff, MR; Dutta, S; Hall, ED; Kupina, NC, 2002) |
| "Nicotine and PBN were both able to significantly reduce hydroxyl radical levels at concentrations of 1, 2." | 1.30 | Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo. ( Earl, CD; Ferger, B; Kuschinsky, K; Oertel, WH; Spratt, C; Teismann, P, 1998) |
| " These results are consistent with previous work highlighting the importance of aberrant amine production in neurological disease and demonstrate that treatments that reduce endogenous melatonin bioavailability can ameliorate experimental PD." | 1.30 | A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. ( Armstrong, SM; Willis, GL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, Y | 1 |
| Qiao, CM | 1 |
| Zhou, Y | 1 |
| Wu, J | 1 |
| Cui, C | 1 |
| Hong, H | 1 |
| Jia, XB | 1 |
| Huang, SB | 1 |
| Yao, L | 1 |
| Zhao, WJ | 1 |
| Shen, YQ | 1 |
| Yuan, Z | 2 |
| Li, D | 2 |
| Feng, P | 2 |
| Xue, G | 2 |
| Ji, C | 2 |
| Li, G | 3 |
| Hölscher, C | 2 |
| Zhang, X | 1 |
| Wang, R | 1 |
| Khlebnikova, NN | 3 |
| Krupina, NA | 3 |
| Bogdanova, NG | 2 |
| Orlova, IN | 3 |
| Zolotov, NN | 2 |
| Philippens, IH | 1 |
| Joosen, MJ | 1 |
| Ahnaou, A | 1 |
| Andres, I | 1 |
| Drinkenburg, WP | 1 |
| Giacoppo, S | 1 |
| Rajan, TS | 1 |
| De Nicola, GR | 1 |
| Iori, R | 1 |
| Rollin, P | 1 |
| Bramanti, P | 1 |
| Mazzon, E | 1 |
| Janakiraman, U | 1 |
| Manivasagam, T | 1 |
| Justin Thenmozhi, A | 1 |
| Dhanalakshmi, C | 1 |
| Essa, MM | 1 |
| Song, BJ | 1 |
| Guillemin, GJ | 1 |
| Kryzhanovskii, GN | 2 |
| Biju, K | 1 |
| Zhou, Q | 1 |
| Imam, SZ | 1 |
| Roberts, JL | 1 |
| Morgan, WW | 1 |
| Clark, RA | 1 |
| Li, S | 1 |
| Suganuma, H | 1 |
| Hirano, T | 1 |
| Arimoto, Y | 1 |
| Inakuma, T | 1 |
| Kupina, NC | 1 |
| Detloff, MR | 1 |
| Dutta, S | 1 |
| Hall, ED | 1 |
| Takahata, K | 1 |
| Shimazu, S | 1 |
| Yoneda, F | 1 |
| Ogawa, M | 1 |
| Iida, Y | 1 |
| Saji, H | 1 |
| Choi, JY | 1 |
| Jang, EH | 1 |
| Park, CS | 1 |
| Kang, JH | 1 |
| Oida, Y | 2 |
| Kitaichi, K | 1 |
| Nakayama, H | 1 |
| Ito, Y | 1 |
| Fujimoto, Y | 1 |
| Shimazawa, M | 2 |
| Nagai, H | 1 |
| Hara, H | 3 |
| Battaglia, G | 1 |
| Farrace, MG | 1 |
| Mastroberardino, PG | 1 |
| Viti, I | 1 |
| Fimia, GM | 1 |
| Van Beeumen, J | 1 |
| Devreese, B | 1 |
| Melino, G | 1 |
| Molinaro, G | 1 |
| Busceti, CL | 1 |
| Biagioni, F | 1 |
| Nicoletti, F | 1 |
| Piacentini, M | 1 |
| Zhu, XR | 1 |
| Maskri, L | 1 |
| Herold, C | 1 |
| Bader, V | 1 |
| Stichel, CC | 1 |
| Güntürkün, O | 1 |
| Lübbert, H | 1 |
| Pankova, NB | 1 |
| Oyagi, A | 1 |
| Izuta, H | 1 |
| Matsunaga, N | 1 |
| Adachi, T | 1 |
| Ferger, B | 1 |
| Spratt, C | 1 |
| Earl, CD | 1 |
| Teismann, P | 1 |
| Oertel, WH | 2 |
| Kuschinsky, K | 1 |
| Willis, GL | 1 |
| Armstrong, SM | 1 |
| Kupsch, A | 1 |
| Sautter, J | 1 |
| Götz, ME | 1 |
| Breithaupt, W | 1 |
| Schwarz, J | 1 |
| Youdim, MB | 1 |
| Riederer, P | 1 |
| Gerlach, M | 1 |
| Sundström, E | 1 |
| Fredriksson, A | 1 |
| Archer, T | 1 |
22 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Body Weight
| Article | Year |
|---|---|
Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzofurans; Body Weight; Disease Models, Ani | 2021 |
A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Body Weight; Brain; Calcium-Bi | 2017 |
Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Body Weight; Cytokines; Diseas | 2018 |
Effect of prolyl endopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on the course of experimental depressive syndrome in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anxiety; Behavior, Animal; Body Weight; Depre | 2013 |
Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Adrenergic alpha-2 Receptor Anta | 2014 |
The Isothiocyanate Isolated from Moringa oleifera Shows Potent Anti-Inflammatory Activity in the Treatment of Murine Subacute Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents; Biomarkers; Body We | 2017 |
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Body Weight; Brain-D | 2017 |
Effect of a prolyl endopeptidase inhibitor benzyloxycarbonyl-alanyl-proline on the development of experimental depressive syndrome in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Body Weight; Depressive Dis | 2009 |
Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cells, Cultured; Chromatography, | 2010 |
Effect of tomato intake on striatal monoamine level in a mouse model of experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Monoamines; Body Weight; Carotenoids | 2002 |
Neuroimmunophilin ligand V-10,367 is neuroprotective after 24-hour delayed administration in a mouse model of diffuse traumatic brain injury.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Body Weight; Brain Inju | 2002 |
Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cell Death; Clorgyline; Disease | 2003 |
Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animal Feed; Animals; Antioxidants; Astrocytes; Blotti | 2005 |
Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; | 2006 |
Transglutaminase 2 ablation leads to defective function of mitochondrial respiratory complex I affecting neuronal vulnerability in experimental models of extrapyramidal disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine Triphosphate; Animals; Basal Ganglia Disease | 2007 |
Non-motor behavioural impairments in parkin-deficient mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Age Factors; Analysis of Variance; Animals; Animals, N | 2007 |
Involvement of brain dopaminergic systems in the development of an MPTP-induced depressive state in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Brain; Depression; Dopamine Agen | 2008 |
Protective effects of SUN N8075, a novel agent with antioxidant properties, in in vitro and in vivo models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Agents; Analysis of Variance; Aniline Compo | 2008 |
Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Cardiotonic Agents; Cyclic N-Oxi | 1998 |
A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biological Availability; Body Weight; Circadi | 1999 |
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Body Weight; Callithrix; Disease Models, Anim | 2001 |
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Di | 1990 |